TrialBreast cancer research : BCR2025

Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study.

Lina Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.